NR3C2 and type 2 diabetes mellitus: Furthermore, finerenone, a non-steroidal mineralocorticoid receptor antagonist (MRA) that decelerated CKD progression and lowered the incidence of adverse cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM) and CKD [5,6], represents the third pillar of the current renoprotective triad in these patients [7].